FI3930715T3 - Sarakatinibi käytettäväksi idiopaattisen keuhkofibroosin hoidossa - Google Patents
Sarakatinibi käytettäväksi idiopaattisen keuhkofibroosin hoidossa Download PDFInfo
- Publication number
- FI3930715T3 FI3930715T3 FIEP20710607.1T FI20710607T FI3930715T3 FI 3930715 T3 FI3930715 T3 FI 3930715T3 FI 20710607 T FI20710607 T FI 20710607T FI 3930715 T3 FI3930715 T3 FI 3930715T3
- Authority
- FI
- Finland
- Prior art keywords
- saracatinib
- pharmaceutically acceptable
- acceptable salt
- ipf
- use according
- Prior art date
Links
- OUKYUETWWIPKQR-UHFFFAOYSA-N saracatinib Chemical compound C1CN(C)CCN1CCOC1=CC(OC2CCOCC2)=C(C(NC=2C(=CC=C3OCOC3=2)Cl)=NC=N2)C2=C1 OUKYUETWWIPKQR-UHFFFAOYSA-N 0.000 title claims 13
- 229950009919 saracatinib Drugs 0.000 title claims 13
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 title claims 10
- 208000036971 interstitial lung disease 2 Diseases 0.000 title claims 10
- 150000003839 salts Chemical class 0.000 claims 13
- 102000012422 Collagen Type I Human genes 0.000 claims 2
- 108010022452 Collagen Type I Proteins 0.000 claims 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims 2
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 claims 2
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 claims 2
- 102000005353 Tissue Inhibitor of Metalloproteinase-1 Human genes 0.000 claims 2
- 108010031374 Tissue Inhibitor of Metalloproteinase-1 Proteins 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 230000007705 epithelial mesenchymal transition Effects 0.000 claims 2
- 210000002744 extracellular matrix Anatomy 0.000 claims 2
- XZXHXSATPCNXJR-ZIADKAODSA-N nintedanib Chemical compound O=C1NC2=CC(C(=O)OC)=CC=C2\C1=C(C=1C=CC=CC=1)\NC(C=C1)=CC=C1N(C)C(=O)CN1CCN(C)CC1 XZXHXSATPCNXJR-ZIADKAODSA-N 0.000 claims 2
- 229960004378 nintedanib Drugs 0.000 claims 2
- 102000008186 Collagen Human genes 0.000 claims 1
- 108010035532 Collagen Proteins 0.000 claims 1
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 claims 1
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 claims 1
- 238000001574 biopsy Methods 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 229920001436 collagen Polymers 0.000 claims 1
- 238000002591 computed tomography Methods 0.000 claims 1
- 230000008021 deposition Effects 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 230000002085 persistent effect Effects 0.000 claims 1
- 230000036573 scar formation Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962811009P | 2019-02-27 | 2019-02-27 | |
| PCT/IB2020/051642 WO2020174420A1 (en) | 2019-02-27 | 2020-02-26 | Method of treating a fibrotic disease or condition or of an interstitial lung disease using a src kinase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3930715T3 true FI3930715T3 (fi) | 2024-08-05 |
Family
ID=69784492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP20710607.1T FI3930715T3 (fi) | 2019-02-27 | 2020-02-26 | Sarakatinibi käytettäväksi idiopaattisen keuhkofibroosin hoidossa |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220117966A1 (https=) |
| EP (1) | EP3930715B1 (https=) |
| JP (2) | JP7547356B2 (https=) |
| CN (1) | CN113811296B (https=) |
| DK (1) | DK3930715T3 (https=) |
| ES (1) | ES2994095T3 (https=) |
| FI (1) | FI3930715T3 (https=) |
| HU (1) | HUE067967T2 (https=) |
| MA (1) | MA55076A (https=) |
| PT (1) | PT3930715T (https=) |
| TW (1) | TWI836022B (https=) |
| WO (1) | WO2020174420A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112674031B (zh) * | 2020-12-03 | 2021-11-30 | 同济大学 | 新型冠状病毒感染的啮齿动物模型的构建方法和用途 |
| US20250161250A1 (en) * | 2022-02-28 | 2025-05-22 | Nuformix Technologies Limited | Compositions and methods for treatment of idiopathic pulmonary fibrosis |
| CN117618436A (zh) * | 2022-08-25 | 2024-03-01 | 广州再极医药科技有限公司 | 一种稠环嘧啶类化合物的用途 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| GB0427697D0 (en) | 2004-12-17 | 2005-01-19 | Astrazeneca Ab | Chemical process |
| US9844528B2 (en) * | 2006-08-24 | 2017-12-19 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
| CN102675282B (zh) * | 2011-03-15 | 2014-12-24 | 广东东阳光药业有限公司 | 取代的喹啉化合物及其使用方法和用途 |
| US20130336889A1 (en) * | 2012-06-14 | 2013-12-19 | National Taiwan University | Nanoparticle and method for detecting or treating a tumor using the same |
| CN105294682B (zh) * | 2014-07-26 | 2017-07-07 | 广东东阳光药业有限公司 | Cdk类小分子抑制剂的化合物及其用途 |
| EP4653015A3 (en) * | 2015-01-26 | 2025-12-31 | Yale University | COMPOSITIONS AND METHODS OF USE OF TYROSINE KINASE INHIBITORS |
| EP3277282B1 (en) * | 2015-04-01 | 2022-10-12 | Istanbul Universitesi Rektorlugu | Dasatinib for use in the treatment, regression or decelerating the progress of fibrotic lung diseases |
| GB201514760D0 (en) * | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds and method of use |
| JP6905662B2 (ja) * | 2015-11-14 | 2021-07-21 | サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． | 置換キノリン化合物の結晶形およびその医薬組成物 |
| EP3228630A1 (en) * | 2016-04-07 | 2017-10-11 | IMBA-Institut für Molekulare Biotechnologie GmbH | Combination of an apelin antagonist and an angiogenesis inhibitor for the treatment of cancer |
| WO2018026441A1 (en) * | 2016-08-01 | 2018-02-08 | The Regents Of The University Of California | Methods for preventing or treating fibrotic diseases |
| WO2018046876A1 (en) * | 2016-09-06 | 2018-03-15 | The University Of Birmingham | Treatment of chronic inflammatory disease |
| CN106692150B (zh) * | 2016-12-21 | 2019-08-20 | 中国人民解放军第三〇二医院 | 尼达尼布在制备预防和治疗肝纤维化与肝硬化的药物中的用途 |
| EP3964214A1 (en) * | 2020-09-02 | 2022-03-09 | Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V. | Modulators of airway basal cells for the treatment or prevention of lung diseases |
-
2020
- 2020-02-26 EP EP20710607.1A patent/EP3930715B1/en active Active
- 2020-02-26 ES ES20710607T patent/ES2994095T3/es active Active
- 2020-02-26 CN CN202080016378.4A patent/CN113811296B/zh active Active
- 2020-02-26 WO PCT/IB2020/051642 patent/WO2020174420A1/en not_active Ceased
- 2020-02-26 JP JP2021550035A patent/JP7547356B2/ja active Active
- 2020-02-26 DK DK20710607.1T patent/DK3930715T3/da active
- 2020-02-26 PT PT207106071T patent/PT3930715T/pt unknown
- 2020-02-26 MA MA055076A patent/MA55076A/fr unknown
- 2020-02-26 HU HUE20710607A patent/HUE067967T2/hu unknown
- 2020-02-26 FI FIEP20710607.1T patent/FI3930715T3/fi active
- 2020-02-26 US US17/434,036 patent/US20220117966A1/en active Pending
- 2020-02-27 TW TW109106616A patent/TWI836022B/zh active
-
2024
- 2024-08-28 JP JP2024146122A patent/JP2024174909A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN113811296A (zh) | 2021-12-17 |
| PT3930715T (pt) | 2024-08-02 |
| ES2994095T3 (en) | 2025-01-17 |
| MA55076A (fr) | 2022-04-20 |
| DK3930715T3 (da) | 2024-08-05 |
| TWI836022B (zh) | 2024-03-21 |
| EP3930715B1 (en) | 2024-05-08 |
| HUE067967T2 (hu) | 2024-12-28 |
| JP2024174909A (ja) | 2024-12-17 |
| CN113811296B (zh) | 2025-05-16 |
| EP3930715A1 (en) | 2022-01-05 |
| JP2022521635A (ja) | 2022-04-11 |
| JP7547356B2 (ja) | 2024-09-09 |
| WO2020174420A1 (en) | 2020-09-03 |
| TW202045180A (zh) | 2020-12-16 |
| US20220117966A1 (en) | 2022-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3930715T3 (fi) | Sarakatinibi käytettäväksi idiopaattisen keuhkofibroosin hoidossa | |
| Borghi et al. | Double-blind comparison between zofenopril and lisinopril in patients with acute myocardial infarction: results of the Survival of Myocardial Infarction Long-term Evaluation-2 (SMILE-2) study | |
| JP2020033360A5 (https=) | ||
| AU2008241012B2 (en) | Tapentadol for treating pain from arthritis | |
| JPWO2013118773A1 (ja) | 特発性炎症性筋疾患の予防又は治療剤 | |
| US20240115548A1 (en) | Sulcardine administration for treatment of acute atrial fibrillation | |
| JP5377852B2 (ja) | リセドロネート組成物およびその使用方法 | |
| JP2024534427A5 (https=) | ||
| JP2017533211A5 (https=) | ||
| EP3053581B1 (en) | Therapeutic agent for osteoporosis | |
| Bryan et al. | Curvularia lunata endocarditis treated with terbinafine: case report | |
| JP2023500060A5 (https=) | ||
| JP2022521635A5 (https=) | ||
| HRP20251043T1 (hr) | Novi oralni farmaceutski pripravak i režim doziranja za terapiju progresivnih fibrozirajućih intersticijskih bolesti pluća | |
| CA2474430A1 (en) | A combination of a thrombolytic agent and levosimendan for the treatment of acute myocardial infarction | |
| Roth et al. | Early thrombolytic therapy does not enhance the recovery of the right ventricle in patients with acute inferior myocardial infarction and predominant right ventricular involvement | |
| JP2021075470A (ja) | 肺線維症の予防または治療のための医薬 | |
| BR112021014499A2 (pt) | Composição farmacêutica para o tratamento de hipertensão pulmonar tromboembólica crônica | |
| Accurso et al. | Final results of a 14-and 28-day study of VX-770 in subjects with CF | |
| Poole-Wilson | Timolol maleate (MK 950) in the treatment of essential hypertension | |
| ES2370145T3 (es) | Ivabradina y su utilización en un método de diagnóstico que emplea el método de angiografía coronaria por tomodensitometría de múltiples cortes. | |
| Kanorskii et al. | Triple antianginal combinations in the treatment of elderly and senile patients with stable angina | |
| Pinter et al. | 26589 Spesolimab, an IL-36R inhibitor, may reduce symptoms of pain in patients with palmoplantar pustulosis–Results from a small pilot study | |
| Huynh | Use of polypills for CVD prevention | |
| Jin et al. | The Therapeutic Effect of Medical Patches Including Isoegomaketone on the Collagen Antibody-induced Arthritis in Mice |